載入中
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
收盤時
US$29.78
−US$1.22 · -3.94%
盤後
US$30.48
+US$0.70 · +2.35%
10月12日 下午5:24 ET
盤中時間採用ET。市場資料可能有所延遲。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日內區間
目前US$29.78
52週區間
目前US$29.78
盤中時間採用ET。市場資料可能有所延遲。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日內區間
目前US$29.78
52週區間
目前US$29.78
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 461.9萬 USD | — | — | — | — |
| 毛利 | −461.9萬 USD | — | — | — | — |
| 研究與開發 | 2.7億 USD | 2.33億 USD | 1.74億 USD | 1.22億 USD | 5591.3萬 USD |
| 銷售、一般及管理費用 | 6358.3萬 USD | 4328.1萬 USD | 3437.5萬 USD | 2621.2萬 USD | 1963.8萬 USD |
| 營業費用 | 3.29億 USD | 2.76億 USD | 2.08億 USD | 1.48億 USD | 7555.1萬 USD |
| 利息收入 | 1468.9萬 USD | 1808.8萬 USD | 1307.7萬 USD | 398.9萬 USD | 46.7萬 USD |
| 利息支出 | 306.2萬 USD | — | — | 398.9萬 USD | — |
| 折舊和攤銷 | 458.3萬 USD | 435.1萬 USD | 358.8萬 USD | 587.8萬 USD | 14.7萬 USD |
| 營業利益 | −3.33億 USD | −2.76億 USD | −2.08億 USD | −1.48億 USD | −7555.1萬 USD |
| 淨利 | −3.29億 USD | −2.56億 USD | −1.92億 USD | −1.4億 USD | −7227.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2020年11月9日 | 1:4 | — | — |
已生效 2020年11月9日
1:4
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.81億0.01%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1.35億0.17%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB1.31億0.07%1853億 USD0.03%US$288.16-0.46%
State Street SPDR S&P Biotech ETFXBI1.19億1.21%98.74億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Value ETFVBR8301.73萬0.12%682億 USD0.05%US$234.71+0.12%
Vanguard Extended Market ETFVXF6949.63萬0.07%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO4774.62萬0.34%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB3745.39萬0.35%108.2億 USD0.44%US$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
